Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-center Phase II Trial to Assess the Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML

NCT00915252 is registered in ClinicalTrials.gov with University Hospital Muenster as lead sponsor.

NCT NCT00915252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00915252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-center Phase II Trial to Assess the Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
Lead sponsor
University Hospital Muenster
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
December 31, 2012
Enrollment
214 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia